Shiiba, Michiyo
Zhang, Bo
Miura, Shin-ichiro
Ike, Amane
Nose, Daisuke
Kuwano, Takashi
Imaizumi, Satoshi
Sugihara, Makoto
Iwata, Atushi
Nishikawa, Hiroaki
Kawamura, Akira
Shirai, Kazuyuki
Yasunaga, Shin’ichiro
Saku, Keijiro
Article History
Received: 19 April 2017
Accepted: 9 August 2017
First Online: 16 August 2017
Change Date: 19 February 2018
Change Type: Correction
Change Date: 19 February 2018
Change Type: Correction
Change Type: Correction
Change Details: Unfortunately, the Fig. 1 was published incorrectly in the original publication of the article. The correct figure is as below.
Change Details: Unfortunately, the Fig.?1 was published incorrectly in the original publication of the article. The correct figure is as below.
Change Date: 19 February 2018
Change Details: Unfortunately, the Fig.?1 was published incorrectly in the original publication of the article. The correct figure is as below.
Compliance with ethical standards
:
: Research and education grants, and payments for consulting and promotional speaking (KeS) were received from MSD Co., SANOFI, Takeda Pharmaceutical Co., Ltd., Bayer, Eli Lilly, Co. (clinical research grant), and TOA EIYO Co. KeS and MS are Directors of NPO Clinical and Applied Science, Fukuoka, Japan. KaS, SM, and KeS had received a grant from the Public Interest Incorporated Foundation of “Clinical Research Promotion Foundation” in Fukuoka, Japan, and part of this work was transferred to NPO Clinical and Applied Science, Fukuoka, Japan. KeS has an Endowed Department of Molecular Cardiovascular Therapeutics (YU, SM), Fukuoka University, supported by MSD Co., Ltd, and an Endowed Department of Community and Emergency Medicine (HN, MS), Fukuoka University, supported by Izumi City, Kagoshima, Japan.